BACKGROUND: Near-infrared (NIR) fluorescence imaging using indocyanine green (ICG) is a promising technique to obtain real-time assessment of the extent and number of colorectal liver metastases during surgery. The current study aims to optimize dosage and timing of ICG administration. MATERIALS AND METHODS: Liver tumors were induced in 18 male WAG/Rij rats by subcapsular inoculation of CC531 rat colorectal cancer cells into three distinct liver lobes. Rats were divided in two groups: imaging after 24 and 48 h or 72 and 96 h after intravenous ICG administration. In each time group, rats were allocated to three dose groups: 0.04, 0.08, or 0.16 mg ICG. Intraoperative imaging and ex vivo measurements were performed using the Mini-FLARE imaging system and confirmed by fluorescence microscopy. Fluorescence intensity was quantified using the Mini-FLARE software and the difference between tumor signal and liver signal (tumor-to-liver ratio; TLR) was calculated. RESULTS: In all 18 rats, all colorectal liver metastases (n = 34), some as small as 1.2 mm, were identified using ICG and the Mini-FLARE imaging system. Average tumor-to-liver ratio (TLR) over all groups was 3.0 ± 1.2. TLR was significantly higher in the 72 h time group compared with other time points. ICG dose did not significantly influence TLR, but a trend was found favoring the 0.08 mg dose group. Fluorescence microscopy demonstrated a clear fluorescent rim around the tumor. CONCLUSIONS: This study demonstrates that colorectal cancer liver metastases can be clearly identified during surgery using ICG and the Mini-FLARE imaging system, with optimal timing of 72 h post-injection and an optimal dose of 0.08 mg (0.25 mg/kg) ICG. NIR fluorescence imaging has the potential to improve intraoperative detection of micrometastases and, thus, the completeness of resection.
BACKGROUND: Near-infrared (NIR) fluorescence imaging using indocyanine green (ICG) is a promising technique to obtain real-time assessment of the extent and number of colorectal liver metastases during surgery. The current study aims to optimize dosage and timing of ICG administration. MATERIALS AND METHODS:Liver tumors were induced in 18 male WAG/Rij rats by subcapsular inoculation of CC531 ratcolorectal cancer cells into three distinct liver lobes. Rats were divided in two groups: imaging after 24 and 48 h or 72 and 96 h after intravenous ICG administration. In each time group, rats were allocated to three dose groups: 0.04, 0.08, or 0.16 mg ICG. Intraoperative imaging and ex vivo measurements were performed using the Mini-FLARE imaging system and confirmed by fluorescence microscopy. Fluorescence intensity was quantified using the Mini-FLARE software and the difference between tumor signal and liver signal (tumor-to-liver ratio; TLR) was calculated. RESULTS: In all 18 rats, all colorectal liver metastases (n = 34), some as small as 1.2 mm, were identified using ICG and the Mini-FLARE imaging system. Average tumor-to-liver ratio (TLR) over all groups was 3.0 ± 1.2. TLR was significantly higher in the 72 h time group compared with other time points. ICG dose did not significantly influence TLR, but a trend was found favoring the 0.08 mg dose group. Fluorescence microscopy demonstrated a clear fluorescent rim around the tumor. CONCLUSIONS: This study demonstrates that colorectal cancer liver metastases can be clearly identified during surgery using ICG and the Mini-FLARE imaging system, with optimal timing of 72 h post-injection and an optimal dose of 0.08 mg (0.25 mg/kg) ICG. NIR fluorescence imaging has the potential to improve intraoperative detection of micrometastases and, thus, the completeness of resection.
Authors: Edward Leen; Piercarlo Ceccotti; Susan J Moug; Paul Glen; John MacQuarrie; Wilson J Angerson; Thomas Albrecht; Joachim Hohmann; Anja Oldenburg; Jorg Peter Ritz; Paul G Horgan Journal: Ann Surg Date: 2006-02 Impact factor: 12.969
Authors: Timothy M Pawlik; Charles R Scoggins; Daria Zorzi; Eddie K Abdalla; Axel Andres; Cathy Eng; Steven A Curley; Evelyne M Loyer; Andrea Muratore; Gilles Mentha; Lorenzo Capussotti; Jean-Nicolas Vauthey Journal: Ann Surg Date: 2005-05 Impact factor: 12.969
Authors: A L Vahrmeijer; J H van Dierendonck; J Schutrups; C J van de Velde; G J Mulder Journal: Cancer Chemother Pharmacol Date: 1999 Impact factor: 3.333
Authors: Dushyant V Sahani; Sanjeeva P Kalva; Kenneth K Tanabe; Sikandar M Hayat; Mary J O'Neill; Elkan F Halpern; Sanjay Saini; Peter R Mueller Journal: Radiology Date: 2004-07-23 Impact factor: 11.105
Authors: Alice C Wei; Paul D Greig; David Grant; Bryce Taylor; Bernard Langer; Steven Gallinger Journal: Ann Surg Oncol Date: 2006-03-10 Impact factor: 5.344
Authors: Jeffrey R Watson; Christian F Gainer; Nikolay Martirosyan; Jesse Skoch; G Michael Lemole; Rein Anton; Marek Romanowski Journal: J Biomed Opt Date: 2015-10 Impact factor: 3.170
Authors: Joost R van der Vorst; Boudewijn E Schaafsma; Merlijn Hutteman; Floris P R Verbeek; Gerrit-Jan Liefers; Henk H Hartgrink; Vincent T H B M Smit; Clemens W G M Löwik; Cornelis J H van de Velde; John V Frangioni; Alexander L Vahrmeijer Journal: Cancer Date: 2013-06-21 Impact factor: 6.860
Authors: Yoshihiko Tashiro; Hannah M Hollandsworth; Hiroto Nishino; Jun Yamamoto; Siamak Amirfakhri; Filemoni Filemoni; Norihiko Sugisawa; Takeshi Aoki; Masahiko Murakami; Robert M Hoffman; Michael Bouvet Journal: In Vivo Date: 2020 Sep-Oct Impact factor: 2.155